Vorapaxar in the Human Endotoxemia Model

Summary

Vorapaxar is a recently approved protease activated receptor - 1 (PAR-1) inhibitor. Platelet inhibition may also exert positive results on coagulation activation and may beneficially influence the inflammatory response. Since vorapaxar is the first available substance of a new class of platelet inhibitors its effects on the human coagulation system and the inflammatory response will be assessed in the well-established human endotoxemia model.

Timeline

Start

2016-06

Primary completion

2016-11-30

Completion

2016-11-30

Drugs

Indications

No indication recorded.